Granted Patent B2

US 12,257,343 · App. 16/609,448 · Granted Mar 25, 2025

Inventors: Jian Hua Gu (Thousand Oaks, CA); Robert Matthew Fesinmeyer (Newbury Park, CA); Rulin Qian (Newbury Park, CA)

Assignee: AMGEN INC.

A61K9/08A61K9/19A61K47/183C07K16/244C07K16/40

Abstract

Claims (17)

1. A liquid pharmaceutical formulation comprising an antibody, a buffer, and at least one oligopeptide selected from Arg-Lys, Arg-Phe, Arg-Pro, Arg-Val, Arg-Ala, Asp-Arg, Lys-Arg, Pro-Arg, Leu-Arg, Val-Arg, Phe-Arg, Arg-Tyr, and Ala-Arg, (ii) the buffer is acetate, glutamate, or phosphate and (iii) the pH of the formulation is from about 4.5 to about 6.5, wherein the formulation has a viscosity of no more than 40 cP at 25° C.

2. The formulation of claim 1 , wherein the antibody is present in a concentration of about 70 mg/mL to 200 mg/mL.

3. The formulation of claim 1 , wherein the antibody is selected from adalimumab, bevacizumab, blinatumomab, cetuximab, conatumumab, denosumab, eculizumab, erenumab, evolocumab, a PCSK9 binding polypeptide, infliximab, natalizumab, panitumumab, prezalumab, rilotumumab, rituximab, romosozumab, tezepelumab, and trastuzumab, or comprises one of the following combinations of a heavy chain and a light chain sequence of an antibody: SEQ ID NOs 18 and 19, SEQ ID NOs 20 and 21, SEQ ID NOs 22 and 23, SEQ ID NOs 24 and 25, SEQ ID NOs 26 and 27, SEQ ID NOs 28 and 29, SEQ ID NOs 30 and 31, SEQ ID NOs 32 and 33, SEQ ID NOs 34 and 35, SEQ ID NOS 36 and 37, SEQ ID NOs 38 and 39, SEQ ID NOs 40 and 41, SEQ ID NOs 42 and 43, SEQ ID NOs 44 and 45, SEQ ID NOs 46 and 47, SEQ ID NOs 48 and 49, SEQ ID NOs 50 and 51, SEQ ID NOs 52 and 53, SEQ ID NOs 54 and 55, SEQ ID NOS 56 and 57, SEQ ID NOs 58 and 59, SEQ ID NOs 60 and 61, SEQ ID NOs 62 and 63, SEQ ID NOs 64 and 65, SEQ ID NOs 66 and 67, SEQ ID NOs 68 and 69, SEQ ID NOs 70 and 71, SEQ ID NOs 72 and 73, SEQ ID NOs 74 and 75, SEQ ID NOS 76 and 77, SEQ ID NOs 78 and 79, SEQ ID NOs 80 and 81, SEQ ID NOs 82 and 83, SEQ ID NOs 84 and 85, SEQ ID NOs 86 and 87, SEQ ID NOs 88 and 89, SEQ ID NOs 90 and 91, SEQ ID NOs 92 and 93, SEQ ID NOs 94 and 95, SEQ ID NOS 96 and 97, SEQ ID NOs 98 and 99, SEQ ID NOs 100 and 101, or SEQ ID NOS 102 and 103.

4. The formulation of claim 1 , wherein the oligopeptide has a concentration of:

a. about 10 mM to about 500 mM or

b. about 100 mM to about 200 mM.

5. The formulation of claim 1 , wherein the oligopeptide is an acetate salt.

6. The formulation of claim 1 , further comprising (i) a second oligopeptide comprising arginine and consisting of two to 10 amino acid residues, wherein the second oligopeptide is a dipeptide comprising a basic, acidic, hydrophobic, or aromatic residue, (ii) one or more amino acids, or (iii) mixtures thereof.

7. The formulation of claim 6 , wherein the second oligopeptide is selected from Arg-Lys, Arg-Pro, Arg-Ala, Asp-Arg, Lys-Arg, Pro-Arg, Val-Arg, Ala-Arg, Phe-Arg, and Arg-Tyr and the one or more amino acids are selected from arginine, proline, n-acetyl arginine, n-acetyl lysine, n-acetyl histidine, and n-acetyl proline.

8. The formulation of claim 1 , wherein the formulation has a pH of from about 5 to about 6.

9. The formulation of claim 1 , wherein the formulation further comprises a surfactant.

10. The formulation of claim 9 , wherein the surfactant is polysorbate 20 or polysorbate 80.

11. The formulation of claim 10 , wherein the surfactant is present at a concentration of about 0.01% in the formulation.

12. The formulation of claim 1 , wherein the formulation is suitable for subcutaneous administration.

13. The formulation of claim 2 , wherein the formulation has a viscosity of equal to or less than about 15 cP at 25° C.

14. The formulation of claim 3 , wherein the antibody is adalimumab, bevacizumab, denosumab, erenumab, evolocumab, infliximab, romosozumab, tezepelumab, or trastuzumab.

15. The formulation of claim 1 , wherein the oligopeptide has a concentration of about 100 mM to about 200 mM.

Assignments (1)

Continuity (2)

References Cited (70)